Featured Interview: The End of the Undruggable

Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments to combat cancers and other conditions. In a recent feature by STAT, Dr. Steve Yang, CO-CEO of WuXi AppTec, explores how this next-generation modality is gaining traction across the biotech industry and describes how WuXi AppTec supports customers from small and emerging biotechs to large pharmas in advancing their pioneering TPD projects across all stages of our CRDMO platform.

In a space defined by long timelines and bold science, translation is everything. From idea to impact, it takes more than science — it takes collaboration, speed, and scale. That’s what we’re here to deliver at WuXi AppTec.

Read the full interview HERE